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ABSTRACT
Risperidone has been found to be useful in the treatment of acute bipolar disorders. This is a case report where risperidone mono
therapy has been found to be effective in prophylaxis of bipolar affective disorder. The pharmacological and clinical implications of
risperidone in the management of BPAD are discussed
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Introduction
Since the introduction of serotonin dopamine antagonists in
psychiatry their role in the management of Bipolar Affective
Disorder (BPAD) have been of immense interest Recently
risperidone has been approved for the treatment of BPAD
by FDA. The earlier studies about the role of atypical
antipsychotics in BPAD are inconclusive. Dwight et al.,
(1994) and Lane et al., (1940) reported emergence of manic
symptoms with risperidone and Tohen et al., (1999) found
that olanzapine was helpful in mixed episodes of BPAD
when used in combination with sodium valproate or lithium
carbonate. Most of the recent studies found that risperidone
is useful in  the management of acute bipolar-mania when
used alone (Khanna et al., 2003) and also when used in
combination with a mood stabilizer(Sachs et al., 2002).No
data are available regarding the role of risperidone mono
therapy in maintenance treatment of BPAD. We are
reporting here a case where risperidone mono therapy  is
found to be effective in the  maintenance treatment of
BPAD.
Case Report
Mr. J.L. is  a 35 year old unmarried male from lower
socioeconomic class. He was diagnosed to have mixed
affective episode in 1992 and was treated with Lithium
1200mg. The patient recovered . However , he stopped
Lithium after four months. He had the second episode in
1996 which was diagnosed as BPAD – mania. He was
treated with Lithium 1200mg, Trifluperazine 10mg and
Chlorpromazine  50mg. Though the first episode was mixed,
patient  had responded well to Lithium. So Lithium was the
natural choice in the second episode. Moreover, his episode
was a Manic episode. Patient had two episodes in 1997
while he was on 1000mg of Lithium as the maintenance
therapy. After his fifth episode in 1998 , Carbamazepine
600mg was added to 1000mg of Lithium as the maintenance
therapy. Despite that the patient had another  episode in
January 1999 during which both lithium and carbamazipine
were tapered and sodium valproate was started and
maintained at a dose of 1500mg. He  had another  manic
episode in Oct. 99 during which risperidone eight milligram
was added to 1500mg of sodium valproate. He stopped
sodium valproate by himself(for financial reasons) during
the maintenance phase and continued taking four milligram
of risperidone.   There   was   no  history   of  substance
use   or  presence   of  any psychosocial stressors during
the period (1996 – 1999)  in which the patient had
experienced frequent episodes. He started working as a
driver and was able to continue working for an uninterrupted
period of three years since his second episode in 1996. He
had only manic and mixed episodes during the course of
illness.  All   the   episodes   were   severe   enough   to
warrant    inpatient treatment. Though the patient was
euthymic without medication from 1992 to 1996 ( four
years) he had five episodes between 1996 and 1999. So it
is very unlikely that the euthymic period between 1999 and
2003 during which he was on Risperidone was a natural
remission. He was brought to the hospital in November
2003 with irritability, decreased need for sleep, increased
libido, increased religiosity, aggressive behaviour,
suspiciousness, decreased need for sleep, feeling of
worthlessness, recurrent thoughts of death. Mental status
examination revealed increased psychomotor activity,
disinhibited  behaviour, overfamilarity, grandiose ideas,
distractibility and mood disturbance changing from elation
to crying spells within the same day. Risperidone was274
increased to eight milligrams, carbamazepine was  started
and gradually increased to 1200mg and   300 mg of
chlorpromazine was added. Currently all other medications
apart from Risperidone have been withdrawn and the
patient is on Risperidone  in the maintenance phase.
Discussion
Risperidone , a benzisoxazole derivative binds with high
affinity to serotonin type 2(5HT2)receptors, dopamine D2
receptors and alpha adrenergic  receptors. Risperidone binds
with lower affinity to the alpha 2 adrenergic receptors but
it does not bind to dopamine D1 or muscarinic cholinergic
receptors The emergence of manic symptoms with
risperidone was reported by Lane et al (1998) in which he
hypothesized that manic symptoms may be due to function
of ratio of 5HT2A receptors occupancy with respect to
D2 receptors occupancy. Similar findings have been
reported by Lidenmayer and Klebanov(1998)and John et
al (1998). But Sachs et al (2002) found that addition of
risperidone to a mood stabilizer was a safe therapy and
was more effective in treatment of acute bipolar mania
.They reported the severity of manic symptoms , chances
of  breakthrough manic and mixed affective episodes, and
Young Mania Rating Scale (YMRS) total score at  endpoint
were  significantly lower in patients receiving a mood
stabilizer and risperidone than patients receiving a mood
stabilizer and a placebo.  Khanna et al(2003) found that
risperidone mono therapy is effective in treatment of acute
bipolar mania and efficacy was seen at all time points
starting with week one and was sustained to treatment end
point. They also reported that antimanic activity of
risperidone was independent of presence or absence of
psychotic features and that the treatment was safe and
generally well tolerated.  Though clinicians have tried
maintaining Bipolar disorder patients on various typical
antipsychotics, no control studies were done in this field.
Moreover due to the higher chances of Tardive Dyskinesia
in Bipolar disorder patients, use of long term typical
antipsychotics are not encouraged in the maintenance
treatment of bipolar disorder. So far there are no studies or
case reports  available about the role of risperidone mono
therapy in maintenance phase of BPAD. A single case
report like this is only of heuristic value. However we
believe that this case is unusually clear as the patient had
interepisodic full remission while he was maintained only
on risperidone. A mood stabilizer has been defined as a “a
drug that alleviates the frequency, intensity, or both of manic,
hypomanic,  depressive, or mixed episodes in patients of
bipolar disorder and that does not increase frequency or
severity of any phase of bipolar disorder”(Bowden
CL,1997). Though in this case risperidone is found to act
like a mood stabilizer we need randomized controlled studies
for a definite conclusion.
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